SCHEMBL2097530

SCHEMBL2097530

CCc1cccc(-c2nc(C)c(C)s2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 1/20 0.45
NISCH Q9Y2I1 1/20 0.44
IDO1 P14902 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40
RARA P10276 1/20 0.40
RARB P10826 1/20 0.40
RARG P13631 1/20 0.40
BCL2 P10415 1/20 0.40
NOTUM Q6P988 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
PTGDR2 Q9Y5Y4 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39
TRPM8 Q7Z2W7 2/20 0.39
AOC3 Q16853 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2097528 0.84 IDO1 (0.40) NISCHIDO1SMN1; SMN2NPC1HPGD
SCHEMBL16603180 0.82 DCK (0.42) NISCHKMT2ARARARARBRARG
SCHEMBL4153015 0.80 KMT2A (0.53) SMN1; SMN2NPC1KMT2AALDH1A1GAA
SCHEMBL427731 0.79 SMN1; SMN2 (0.59) SMN1; SMN2NPC1HPGDKMT2ARARA
SCHEMBL27283953 0.78 SMN1; SMN2 (0.47) HAO1SMN1; SMN2NPC1HPGDKMT2A
Hydrochloric Acid SCHEMBL3265116 0.77 SMN1; SMN2 (0.58) SMN1; SMN2NPC1HPGDKMT2ARARA
SCHEMBL2094527 0.77 DCK (0.53) TRPM8
SCHEMBL1091789 0.77 ALDH1A1 (0.55) SMN1; SMN2NPC1HPGDKMT2AALDH1A1
SCHEMBL2089024 0.77 KMT2A (0.64) SMN1; SMN2NPC1KMT2ATRPM8
SCHEMBL21351047 0.75 RAB9A (0.61) SMN1; SMN2NPC1KMT2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 HAO1 1261/4885NISCH 2180/4885IDO1 2665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.